dr. chowdhury on pembrolizumab plus pazopanib in rcc
Published 7 years ago • 537 plays • Length 2:17Download video MP4
Download video MP3
Similar videos
-
0:58
dr. chowdhury on separate roles of pazopanib and pembrolizumab in rcc
-
0:53
dr. chowdhury on sequencing of immunotherapy regimens for rcc
-
2:24
pazopanib and pembrolizumab: a dangerous combination for the treatment of rcc
-
2:58
real world effectiveness of pazopanib in patients with intermediate risk renal cell carcinoma
-
6:30
pembrolizumab in combination with pazopanib
-
5:40
pazopanib and sunitinib in renal cell carcinoma
-
0:54
dr. sankhala on the significance of trc105/pazopanib in angiosarcoma
-
7:14
dosing sunitinib and pazopanib in renal cell carcinoma
-
1:47
dr. schmidinger on side effects from targeted agents in renal cell cancer
-
3:54
treating intermediate and favorable-risk renal cell carcinoma
-
0:25
copy of dr. choudhury on immunotherapy in metastatic crpc
-
2:16
dr. amin on toxicities with immunotherapy/tki combinations in rcc
-
8:27
checkpoint inhibition in renal cell carcinoma
-
1:53
dr. spigel on pembrolizumab/chemo combo in first-line nsclc
-
0:59
dr. molina discusses recent pazopanib clinical trials
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
1:00
adjuvant pembrolizumab for bladder cancer
-
1:03
dr. pal on the sequencing of immunotherapy for urothelial carcinoma
-
2:20
dr. lara on the fda approval of adjuvant sunitinib in rcc